StockNews.AI
CRMD
StockNews.AI
154 days

CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025

1. CRMD to report Q4 and FY 2024 financial results on March 25, 2025. 2. DefenCath launched in inpatient and outpatient settings in 2024. 3. New clinical studies for TPN and pediatric HD patients to start in 2025. 4. DefenCath received FDA approval on November 15, 2023.

Earnings
+4.09%Current Return
VS
+0.44%S&P 500
$10.4703/18 08:42 AM EDTEvent Start
$10.898203/19 03:17 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

The scheduled earnings report may showcase growth from DefenCath. Historical precedence shows positive earnings lead to price increases.

How important is it?

Financial results can significantly inform investor sentiment and stock valuation. DefenCath's recent launch and clinical studies increase future earnings visibility.

Why Short Term?

Upcoming financial results and updates may drive immediate market reactions. Positive news about DefenCath could impact stock in coming weeks.

Related Companies

PFEJNJGILD
March 18, 2025 08:30 ET  | Source: CorMedix, Inc. BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Tuesday, March 25, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, March 25th @ 8:30am ETDomestic: 1-844-481-2557International: 1-412-317-0561Conference ID: 10197392Webcast: Webcast Link    About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas. For more information visit: www.cormedix.com. Investor Contact:Dan FerryManaging DirectorLifeSci Advisorsdaniel@lifesciadvisors.com (617) 430-7576

Related News